Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Ver

Indication
Low Grade Serous Ovarian Cancer

Other upcoming events for VSTM

Patent ExpiryPatent/Exclusivity Expiry: AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Ver — VSTM Phase 3 Readout | BioSniper